Roivant Sciences Ltd

Company Profile

Roivant Sciences Ltd had its IPO on 2021-10-01 under the ticker symbol ROIV.

The company operates in the Healthcare sector and Biotechnology industry. Roivant Sciences Ltd has a staff strength of 904 employees.

Stock update

Shares of Roivant Sciences Ltd opened at $11.39 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $11.16 - $11.68, and closed at $11.22.

This is a -2.52% slip from the previous day's closing price.

A total volume of 3,641,357 shares were traded at the close of the day’s session.

In the last one week, shares of Roivant Sciences Ltd have slipped by -3.94%.

Roivant Sciences Ltd's Key Ratios

Roivant Sciences Ltd has a market cap of $9.01 billion, indicating a price to book ratio of 4.3753 and a price to sales ratio of 104.1739.

In the last 12-months Roivant Sciences Ltd’s revenue was $78.59 million with a gross profit of $-477063000 and an EBITDA of $-1037155008. The EBITDA ratio measures Roivant Sciences Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Roivant Sciences Ltd’s operating margin was -1347.81% while its return on assets stood at -27.95% with a return of equity of -77.38%.

In Q2, Roivant Sciences Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 400.7%.

Roivant Sciences Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Roivant Sciences Ltd’s profitability.

Roivant Sciences Ltd stock is trading at a EV to sales ratio of 78.4713 and a EV to EBITDA ratio of -3.1722. Its price to sales ratio in the trailing 12-months stood at 104.1739.

Roivant Sciences Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$2.14 billion

Total Liabilities

$245.00 million

Operating Cash Flow

$105000.00

Capital Expenditure

$403000

Dividend Payout Ratio

0%

Roivant Sciences Ltd ended 2024 with $2.14 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.14 billion while shareholder equity stood at $910.73 million.

Roivant Sciences Ltd ended 2024 with $0 in deferred long-term liabilities, $245.00 million in other current liabilities, in common stock, $-4064570000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.43 billion and cash and short-term investments were $1.43 billion. The company’s total short-term debt was $55,754,000 while long-term debt stood at $385.07 million.

Roivant Sciences Ltd’s total current assets stands at $1.56 billion while long-term investments were $296.24 million and short-term investments were $0. Its net receivables were $39.91 million compared to accounts payable of $50.04 million and inventory worth $4.23 million.

In 2024, Roivant Sciences Ltd's operating cash flow was $105000.00 while its capital expenditure stood at $403000.

Comparatively, Roivant Sciences Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$11.22

52-Week High

$12.84

52-Week Low

$2.87

Analyst Target Price

$15.63

Roivant Sciences Ltd stock is currently trading at $11.22 per share. It touched a 52-week high of $12.84 and a 52-week low of $12.84. Analysts tracking the stock have a 12-month average target price of $15.63.

Its 50-day moving average was $11.31 and 200-day moving average was $9.02 The short ratio stood at 6.16 indicating a short percent outstanding of 0%.

Around 3448.1% of the company’s stock are held by insiders while 5851.8% are held by institutions.